Olive baboons: A non-human primate model for testing dengue virus type 2 replication

International Journal of Infectious Diseases

Volumn 17, Issue 12, 2013, Pages

  Valdés, Iris ^a   Gil, Lázaro ^a   Castro, Jorge ^a   Odoyo, Damián ^b   Hitler, Rikoi ^b   Munene, Elephas ^b   Romero, Yaremis ^a   Ochola, Lucy ^b   Cosme, Karelia ^a   Kariuki, Thomas ^b   Guillén, Gerardo ^a   Hermida, Lisset ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b INSTITUTE OF PRIMATE RESEARCH   (Kenya)

Author keywords

African green monkeys; Baboons; Dengue; Non human primates; Vaccine; Viremia

Indexed keywords

IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ARTICLE; CHLOROCEBUS; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 2; EXPOSURE; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; NONHUMAN; PAPIO ANUBIS; PRIMATE MODEL; SPECIES COMPARISON; VIREMIA; VIRUS DETECTION; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS TITRATION;

AFRICAN GREEN MONKEYS; BABOONS; DENGUE; NON-HUMAN PRIMATES; VACCINE; VIREMIA;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BODY TEMPERATURE; CERCOPITHECINAE; CERCOPITHECUS AETHIOPS; DENGUE; DENGUE VIRUS; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN G; NEUTRALIZATION TESTS; TIME FACTORS; VIRAL LOAD; VIREMIA; VIRUS REPLICATION;

EID: 84888431175     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.08.007     Document Type: Article

References (29)

1. World Health Organization. Dengue and dengue haemorrhagic fever. 2011. (accessed 5 Sept 2011). http://www.who.int/mediacentre/factsheets/fs117/en/2009.
2. Gubler D.J. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 2002, 10:100-103.
3. Halstead S.B. Dengue. Curr Opin Infect Dis 2002, 15:471-476.
4. Bente D.A., Rico-Hesse R. Models of dengue virus infection. Drug Discov Today Dis Models 2006, 3:97-103.
5. Halstead S.B., Shotwell H., Casals J. Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J Infect Dis 1973, 128:7-14.
6. Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., Draper K., et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004, 78:4761-4775.
7. Deubel V., Kinney R.M., Esposito J.J., Cropp C.B., Vorndam A.V., Monath T.P., et al. Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue. J Gen Virol 1988, 69(Pt 8):1921-1929.
8. Putnak J.R., Coller B.A., Voss G., Vaughn D.W., Clements D., Peters I., et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005, 23:4442-4452.
9. Simmons M., Porter K.R., Hayes C.G., Vaughn D.W., Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol 2006, 80:9577-9585.
10. Sun W., Nisalak A., Gettayacamin M., Eckels K.H., Putnak J.R., Vaughn D.W., et al. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. J Infect Dis 2006, 193:1658-1665.
11. Clements D.E., Coller B.A., Lieberman M.M., Ogata S., Wang G., Harada K.E., et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010, 28:2705-2715.
12. Bernardo L., Izquierdo A., Alvarez M., Rosario D., Prado I., Lopez C., et al. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res 2008, 80:194-199.
13. Kaufman B.M., Summers P.L., Dubois D.R., Eckels K.H. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg 1987, 36:427-434.
14. Kochel T.J., Watts D.M., Gozalo A.S., Ewing D.F., Porter K.R., Russell K.L. Cross-serotype neutralization of dengue virus in Aotus nancymae monkeys. J Infect Dis 2005, 191:1000-1004.
15. Martin J., Hermida L., Castro J., Lazo L., Martinez R., Gil L., et al. Viremia and antibody response in green monkeys (Chlorocebus aethiops sabaeus) infected with dengue virus type 2: a potential model for vaccine testing. Microbiol Immunol 2009, 53:216-223.
16. Martin J., Hermida L., Castro J., Romero Y., Cardosa J., Guillen G. Viremia and the magnitude of the immune response upon infection of green monkeys with dengue virus type 2 are strain-dependent. Curr Microbiol 2009, 59:579-583.
17. Valdes I., Hermida L., Martin J., Menendez T., Gil L., Lazo L., et al. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine 2009, 27:995-1001.
18. Kennedy R.C., Shearer M.H., Hildebrand W. Nonhuman primate models to evaluate vaccine safety and immunogenicity. Vaccine 1997, 15:903-908.
19. Perry D.L., Bollinger L., White G.L. The baboon (Papio spp.) as a model of human Ebola virus infection. Viruses 2012, 4:2400-2416.
20. Churdboonchart V., Bhamarapravati N., Peampramprecha S., Sirinavin S. Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am J Trop Med Hyg 1991, 44:481-493.
21. Kaufman B.M., Summers P.L., Dubois D.R., Eckels K.H. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg 1987, 36:427-434.
22. Roehrig J.T., Hombach J., Barrett A.D. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008, 21:123-132.
23. Carlsson H.E., Schapiro S.J., Farah I., Hau J. Use of primates in research: a global overview. Am J Primatol 2004, 63:225-237.
24. Goodman M. The genomic record of humankind's evolutionary roots. Am J Hum Genet 1999, 64:31-39.
25. Wolf R.F., Papin J.F., Hines-Boykin R., Chavez-Suarez M., White G.L., Sakalian M., et al. Baboon model for West Nile virus infection and vaccine evaluation. Virology 2006, 355:44-51.
26. Whitby D., Stossel A., Gamache C., Papin J., Bosch M., Smith A., et al. Novel Kaposi's sarcoma-associated herpesvirus homolog in baboons. J Virol 2003, 77:8159-8165.
27. Papin J.F., Verardi P.H., Jones L.A., Monge-Navarro F., Brault A.C., Holbrook M.R., et al. Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice. Proc Natl Acad Sci U S A 2011, 108:14926-14931.
28. Green C.J., Knight J., Precious S., Simpkin S. Ketamine alone and combined with diazepam or xylazine in laboratory animals: a 10 year experience. Lab Anim 1981, 15:163-170.
29. Halstead S. Dengue 2008, Imperial College Press, London. First ed.